Dr. Richard T. Silver Discusses the Use of Interferons in MPNs

Richard T. Silver, MD
Published: Friday, Mar 01, 2013

Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms (MPNs).

Silver says that the thought to use interferon in MPNs such as essential thrombocythemia stemmed from its activity against hematopoietic cells. In patients with polycythemia vera, interferon has demonstrated long term remission. In patients with essential thrombocythemia, 80-90% response rates have been observed. Silver says that interferon can be used in women who are pregnant, bringing down platelet count, without leukomogenic or teratogenic qualities that would affect the fetus, unlike hydroxyurea.

SELECTED
LANGUAGE
Richard T. Silver, MD, Professor of Medicine, Director, Leukemia and Myleoproliferative Center, New York Presbyterian-Weill Cornell Medical Center, discusses the use of interferons in myeloproliferative neoplasms (MPNs).

Silver says that the thought to use interferon in MPNs such as essential thrombocythemia stemmed from its activity against hematopoietic cells. In patients with polycythemia vera, interferon has demonstrated long term remission. In patients with essential thrombocythemia, 80-90% response rates have been observed. Silver says that interferon can be used in women who are pregnant, bringing down platelet count, without leukomogenic or teratogenic qualities that would affect the fetus, unlike hydroxyurea.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Atlanta: Advances in the Treatment of Chronic Lymphocytic LeukemiaFeb 28, 20190.5
Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic MalignanciesFeb 28, 20192.0
Publication Bottom Border
Border Publication
x